The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.

This is a randomized, double-masked, parallel group, dose-comparison, exploratory study of four doses of iontophoretic delivery of dexamethasone phosphate ophthalmic solution in patients with non-infectious anterior segment uveitis. The current study will evaluate the safety, tolerability, and efficacy of this technology at the four dose levels to determine a safe effective dose appropriate for future trials.

Inclusion Criteria:

• Non-infectious anterior uveitis

Exclusion Criteria:

• Uveitis of infectious etiology
• Previous anterior uveitis episode ≤ 4 weeks prior to baseline
• Intraocular pressure (IOP) ≥ 25 mmHg at baseline, a history of glaucoma, and/or patients who require ocular anti-hypertensive medications
• Topical corticosteroid treatment in either eye < 48 hours prior to baseline
• Oral corticosteroid or intraorbital corticosteroid treatment in either eye < 2 weeks prior to baseline
• Active intermediate or posterior uveitis